- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02846337
Ultrafiltration Versus Medical Therapies in the Management of the Cardio Renal Syndrome (UF-CARE)
Type 2 cardio renal syndrome is defined by the occurrence or the exacerbation of a kidney failure induced by a chronic heart failure. Sodium overload is one of the main causes leading to the occurrence or the exacerbation of this syndrome. Some patients have a massive sodium retention on which medications are not effective enough. These patients have no further therapeutic options because of the refractory congestion and a 3-months mortality rate around 15%, frequent rehospitalization (3-months rehospitalization rate at 71%) and an excessively impaired quality of life.
For those refractory heart failure with cardio renal syndrome, nephrology departments resort to non-medication sodium extraction (hemodialysis, peritoneal dialysis, isolated ultrafiltration). Between 2002 and 2008, 927 French patients would have start dialysis in this situation. In 2013, 174 patients start dialysis in 97 dialysis centers. French National Authority of Health recently published new Good Practice Guidance thereupon, strengthened by the increasing number of publications and the widespread use of this technique. There is therefore a consensus among professionals about the benefits of such a technique in those indications. However, bibliographical data are not strong enough to support a strong level of evidence. None of foresight strategies have been compared to others in a proper randomized controlled trial, and there is no clue about any suspected superiority from one strategy to another.
So far, the investigators propound invasive, expensive and not validated techniques to patients with functional and vital prognosis altered. The investigators think it's essential to prove the efficacy of such an approach. They wish to quantify those techniques impact on rehospitalization, with a consideration for the potential survival impact.
It seems unethical to evaluate separated techniques, taking in account that patients with severe heart failure will switch from one technique to another among their care. It is therefore crucial to validate benefits from an invasive procedure (hemodialysis, peritoneal dialysis, isolated ultrafiltration) compared to a medication-restricted care.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Laurent JUILLARD, Pr
- Phone Number: +33 (0)472 110 159
- Email: laurent.juillard@chu-lyon.fr
Study Contact Backup
- Name: Laurent MAGAUD
- Phone Number: +33 (0)472 112 805
- Email: laurent.magaud@chu-lyon.fr
Study Locations
-
-
Rhones Alpes
-
Lyon, Rhones Alpes, France, 69003
- Recruiting
- Hospices Civils de Lyon, Hôpital E Herriot, Service de néphrologie, 5 place d'Arsonval
-
Contact:
- Laurent JUILLARD, Pr
- Phone Number: +33 (0)472 110 159
- Email: laurent.juillard@chu-lyon.fr
-
Contact:
- Laurent MAGAUD
- Phone Number: +33 (0)472 112 805
- Email: laurent.magaud@chu-lyon.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Severe heart failure with recurring congestive symptoms and at least one the following criteria :
- At least 2 hospitalization > 24 hours for congestive symptoms among the 12 months before the inclusion, whose latest one was in the 6 months before the inclusion
- Persistent congestive symptoms throughout 30 days (case history) before the randomization: dyspnea NYHA III or IV, lower limbs edema and/or ascites.
- Diuretic treatment with at least 250mg furosemide per day (or 6mg bumetanide)during at least 1 month
- Cardiac medical treatment enhanced by the European cardiology society guidance (except intolerance, and/or contraindication) and according to patient cardiologist.
- Non terminal kidney disease or failure : estimated glomerular filtration rate (GFR) (CKD-Epi formula) between 20 and 90 mL/min/1.73m² (or GFR estimated between 60 and 90 mL/min/1.73m² with proteinuria and/or hematuria) and urea rate under 50mmol/L
Exclusion Criteria:
- Cardiogenic shock or situations that contraindicate the ultrafiltration technique elsewhere than shock room
- Patient who already had long course ultrafiltration for more than 3 months, or not available because of end-stage renal failure
- Biventricular pacemaker implementation, single or dual chamber pacemaker implementation, or defibrillator implementation up to 15 days before the inclusion
- Vasoactive drugs ambulatory treatment (dobutamine, dopamine, adrenalin, noradrenalin)
- General condition incompatible with any ultrafiltration techniques
- Age under 18
- Pregnant or lactating women
- Law-protected patients
- Patients that can't submit to the follow-up for geographical, social or mental reasons
- Unwillingness to be treated by ultrafiltration techniques
- Patients who don't belong to the national social security system, or similar system.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ULTRAFILTRATION
The ultrafiltration sodium-overload extraction will be chosen by the patient nephrologist and the patient himself (according to his comorbidities) among the following one: peritoneal dialysis (at least a daily contact), hemodialysis (>1 session per week) or isolated ultrafiltration (>1 session per week).
Ultrafiltration technique could change throughout the care
|
Peritoneal dialysis: at least one daily contact, 5 days a week minimum, with a hypertonic solution. Le number of contact et the stasis duration will be decided by the practitioner. Hemodialysis: at least one hemodialysis per week, one hemofiltration and/or hemodiafiltration per week, and at least 2 liter of ultrafiltrate extraction per week. In case of serious interdialytic weight gain, and/or hemodynamic unsteadiness, sessions can be up to 6 per weeks. Sessions duration will be adjusted to the needful ultrafiltrate and hemodynamic tolerance. Isolated ultrafiltration: at least once a week, and includes an extraction of minimum 2 liter ultrafiltrate in less than 4 hours. It could be done, according to routines and department capacity, on a hemodialysis generator, plasmatic exchange generator, or mobile ultrafiltration device. |
Other: ENHANCED MEDICAL TREATMENT
The control group called "enhanced medical treatment" will not benefit of ultrafiltration (except refractory pulmonary edema, or terminal kidney failure requiring extra renal depuration).
These situations will not be considered as protocol violation, because they are scientifically indicated for extra renal depuration.
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
death and/or unscheduled hospitalization
Time Frame: up to 12 months post-randomization
|
The primary outcome measure is a combined measure including death whatever the cause, and/or unscheduled hospitalization for acute decompensated heart failure.
For each groups, deaths, cause and time of deaths will be recorded.
Hospitalization date, duration, location, and reason will be recorded.
The "hospitalization" setting and the "acute decompensated heart failure" setting will be endorsed by an event validation committee.
|
up to 12 months post-randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Survival
Time Frame: 12 months
|
number of days spent alive and not hospitalized
|
12 months
|
Survival
Time Frame: 12 months
|
Intervention effect on one-year overall survival
|
12 months
|
Hospitalization for acute decompensated heart failure
Time Frame: up to 12 months post- randomization
|
Intervention effect on :
|
up to 12 months post- randomization
|
Change in NYHA classification
Time Frame: randomization day and 12 months post randomization.
|
New York Health Association - Measurement scale to classify heart failure in 4 stages (stage 1 ; no symptoms)
|
randomization day and 12 months post randomization.
|
Change in 6MWT - Six-Minute Walk Test
Time Frame: randomization day and 12 months post randomization.
|
Six-minute walk test with an experimented physiologist.
The distance in meters is retained.
|
randomization day and 12 months post randomization.
|
Change in MLwHF form
Time Frame: randomization day and 12 months post randomization.
|
Minnesota Living with Heart Failure - Quality of life self-administered survey focusing on heart failure symptoms (21 items with 1 : slightly to 5 : al lot) Safety issue?
0 Yes 1 No
|
randomization day and 12 months post randomization.
|
Change in SF36 form
Time Frame: randomization day and 12 months post randomization.
|
Short Form 36 : Quality of life self-administered survey with 36 items about 8 dimensions including a physical and mental score.
|
randomization day and 12 months post randomization.
|
Death occurrence attributable to ultrafiltration technique
Time Frame: up to 12 months post- randomization
|
Safety: Death occurrence attributable to ultrafiltration technique, validated by an independent supervisory board, and any adverse event.
|
up to 12 months post- randomization
|
Change in Brain Natriuretic Peptide and/or NT-Probating Natriuretic Peptide rate
Time Frame: randomization day and 12 months post randomization
|
Following biological features variation : Brain Natriuretic Peptide (BNP) and/or NT-ProBNP
|
randomization day and 12 months post randomization
|
Change in total bilirubin rate
Time Frame: randomization day, then 3, 6 and 12 months post randomization
|
Following biological features variation : total bilirubin
|
randomization day, then 3, 6 and 12 months post randomization
|
Change high-sensitivity T troponin rate
Time Frame: randomization day and 12 months post randomization
|
Following biological features variation : high-sensitivity T troponin
|
randomization day and 12 months post randomization
|
Change in hemoglobin rate
Time Frame: randomization day and 12 months post randomization
|
Following biological features variation : hemoglobin
|
randomization day and 12 months post randomization
|
Change in Left ventricular ejection fraction (LVEF)
Time Frame: randomization day and 12 months post randomization
|
Following echocardiographic parameters features : left systolic function (LVEF)
|
randomization day and 12 months post randomization
|
Change in Tricuspid annular plane systolic excursion (TAPSE)
Time Frame: randomization day and 12 months post randomization
|
Following echocardiographic parameters features :right systolic function (TAPSE)
|
randomization day and 12 months post randomization
|
Change in tricuspid annular velocity
Time Frame: randomization day and 12 months post randomization
|
Following echocardiographic parameters features : right systolic function assessed by tricuspid annular velocity measured with Pulsed Doppler tissue imaging
|
randomization day and 12 months post randomization
|
Change in transmitral patterns classification
Time Frame: randomization day and 12 months post randomization
|
Following echocardiographic parameters features : left diastolic function assessed by transmitral patterns classification
|
randomization day and 12 months post randomization
|
Change in E/E' ratio
Time Frame: randomization day and 12 months post randomization
|
Following echocardiographic parameters features : E/E'
|
randomization day and 12 months post randomization
|
Change in pulmonary artery systolic pressure (PASP)
Time Frame: randomization day and 12 months post randomization
|
Following echocardiographic parameters features : pulmonary artery systolic pressure (PASP)
|
randomization day and 12 months post randomization
|
Change in Surface of the Left Atrium
Time Frame: randomization day and 12 months post randomization
|
Following echocardiographic parameters features : Surface of the Left Atrium
|
randomization day and 12 months post randomization
|
Change in right atrial pressure
Time Frame: randomization day and 12 months post randomization
|
Following echocardiographic parameters features : Impact on right ventricular function assessed by right atrial pressure
|
randomization day and 12 months post randomization
|
Change in cardiac index
Time Frame: randomization day and 12 months post randomization
|
Following echocardiographic parameters features : cardiac index
|
randomization day and 12 months post randomization
|
Change in cardiac flow
Time Frame: randomization day and 12 months post randomization
|
Following echocardiographic parameters features : cardiac flow
|
randomization day and 12 months post randomization
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Laurent JUILLARD, Hospices Civils de Lyon, 69002 LYON France
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 69HCL15_0077
- 2016-A00518-43 (Other Identifier: ID-RCB)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardio-renal Syndrome
-
Hospital Civil de GuadalajaraCompleted
-
Ankara UniversityCompletedCardiorenal SyndromeTurkey
-
Horng ChenFlowMedica, Inc.TerminatedCardiorenal SyndromeUnited States
-
HaEmek Medical Center, IsraelWithdrawn
-
Mayo ClinicNational Heart, Lung, and Blood Institute (NHLBI)CompletedCardiorenal Syndrome (CRS)United States
-
Maimonides Medical CenterWithdrawn
-
Göteborg UniversitySahlgrenska University Hospital, SwedenCompletedCardiorenal SyndromeSweden
-
National University Hospital, SingaporeChangi General Hospital; National Heart Centre Singapore; Singapore Clinical...UnknownCardio-Renal SyndromeSingapore
-
Duke UniversityNational Heart, Lung, and Blood Institute (NHLBI); Nuwellis, Inc.Completed
-
Virginia Commonwealth UniversityTerminatedCongestive Heart Failure | Cardiorenal SyndromeUnited States
Clinical Trials on ULTRAFILTRATION
-
University of Campinas, BrazilFundação de Amparo à Pesquisa do Estado de São PauloCompletedCoronary Artery Disease | Cardiac Surgical ProceduresBrazil
-
Christiana Care Health ServicesDaxor CorporationCompletedCongestive Heart FailureUnited States
-
Manchester University NHS Foundation TrustManchester Metropolitan University; University of Manchester; University of BirminghamCompletedHaemodynamic InstabilityUnited Kingdom
-
Hospices Civils de LyonRecruitingAcute Kidney InjuryFrance
-
Fresenius Medical Care Deutschland GmbHTerminatedAcute Heart Failure | Volume Overload | Cardiac DecompensationSweden, Switzerland, Germany
-
Kasr El Aini HospitalCompletedCongenital Cardiac DisordersEgypt
-
Belfast Health and Social Care TrustRecruitingFluid OverloadUnited Kingdom
-
IWK Health CentreRecruitingCongenital Heart DiseaseCanada
-
Konkuk University Medical CenterRecruiting
-
Centro Cardiologico MonzinoCompleted